Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
October 2 – Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S.